Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07894770Not yet recruiting
Open-label, single-arm trial of ropivacaine in labor pain, sponsored by General Hospital of Ningxia Medical University. Primary endpoint: 90% effective dose of ropivacaine. Planned start Jun 2027; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07894770.